Persistent URL of this record https://hdl.handle.net/1887/3276391
Documents
-
- Download
- 122782042_publishedVersion_None
- Publisher's Version
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC
- All authors
- Herbst, R.S.; Garon, E.B.; Kim, D.W.; Cho, B.C.; Gervais, R.; Perez-Gracia, J.L.; Han, J.Y.; Majem, M.; Forster, M.D.; Monnet, I.; Novello, S.; Gubens, M.A.; Boyer, M.; Su, W.C.; Samkari, A.; Jensen, E.H.; Kobie, J.; Piperdi, B.; Baas, P.
- Date
- 2021-10-01
- Volume
- 16
- Issue
- 10
- Pages
- 1718 - 1732